Definition
An enantiomer is one of two molecular forms that are mirror images of each other but cannot be superimposed — much like a left hand and a right hand. Enantiomers have identical chemical formulas and the same atomic connections, but their three-dimensional spatial arrangements are non-superimposable reflections. This property is called chirality (from the Greek word for "hand"), and the central atom around which the asymmetry occurs is called a chiral center or stereocenter.
In pharmacology, enantiomers are critically important because biological systems — receptors, enzymes, transporters — are themselves chiral. A drug receptor is like a glove: it fits one hand better than the other. As a result, two enantiomers of the same drug molecule can have dramatically different pharmacological properties, including different potencies, different side effect profiles, different rates of metabolism, and even entirely different therapeutic effects.
Chirality in Chemistry
The Chiral Center
Most drug molecules that exist as enantiomers contain at least one carbon atom bonded to four different chemical groups. This carbon is the chiral center, and it creates the possibility of two distinct spatial arrangements. By convention, these are designated using the R/S naming system (based on the spatial priority of attached groups) or the older D/L system. In clinical pharmacology, enantiomers are also commonly referred to by the direction in which they rotate polarized light: dextrorotatory (+) or levorotatory (-).
Racemic Mixtures
When a chiral drug is synthesized using standard chemical methods, the result is typically a racemic mixture — an equal 50:50 blend of both enantiomers. A racemic mixture is designated by the prefix (±) or the term "racemic." Separating a racemic mixture into its individual enantiomers requires specialized techniques such as chiral chromatography or enzymatic resolution. For more on this concept, see racemic mixture.
Ketamine's Two Enantiomers
Ketamine has one chiral center, giving rise to two enantiomers:
S-Ketamine (Esketamine)
The S-enantiomer, commonly called esketamine, has approximately three to four times greater affinity for the NMDA receptor than R-ketamine. This higher affinity translates to greater anesthetic potency per milligram, stronger dissociative effects, and a different clinical profile. Esketamine is the active ingredient in Spravato, the FDA-approved nasal spray for treatment-resistant depression. For a detailed profile, see our esketamine glossary entry.
Key characteristics of S-ketamine:
- Higher NMDA receptor binding affinity
- More potent analgesic and anesthetic
- Stronger dissociative and psychotomimetic effects at equivalent doses
- Greater affinity for opioid receptors
- Faster hepatic clearance than R-ketamine
R-Ketamine (Arketamine)
The R-enantiomer, called arketamine, has lower NMDA receptor affinity but has generated significant research interest due to preclinical evidence suggesting it may have:
- Equal or greater antidepressant efficacy in animal models, despite weaker NMDA binding
- Fewer dissociative side effects, potentially improving tolerability
- Longer-lasting antidepressant effects in some preclinical paradigms
- A mechanism that may rely more heavily on AMPA receptor activation and BDNF signaling
Arketamine is currently in clinical trials for depression. For more, see our arketamine entry.
Why Enantiomers Matter Clinically
Different Receptor Profiles
The two ketamine enantiomers interact differently not only with the NMDA receptor but with multiple targets throughout the brain. S-ketamine binds more strongly to sigma receptors, opioid receptors, and dopamine transporters. R-ketamine may have preferential effects on certain intracellular signaling cascades. These differences mean that a patient receiving racemic ketamine (the standard clinical formulation) is effectively receiving two drugs simultaneously, each with its own pharmacological profile.
Racemic vs. Single-Enantiomer Therapy
The choice between racemic ketamine and a single-enantiomer formulation has significant clinical implications. Racemic ketamine, used in most IV infusion clinics and oral/sublingual formulations, delivers both enantiomers and their combined pharmacological effects. Single-enantiomer esketamine (Spravato) was developed in part to create a patentable, FDA-approvable formulation, but some clinicians and researchers argue that the racemic form may offer a more balanced therapeutic profile.
For a detailed comparison, see racemic vs. esketamine.
Metabolism Differences
The two enantiomers are metabolized at different rates by hepatic cytochrome P450 enzymes. S-ketamine undergoes faster N-demethylation to S-norketamine, while R-ketamine is metabolized more slowly, resulting in a longer half-life. This difference in clearance affects the duration of action and the ratio of parent drug to metabolite in the bloodstream after administration of racemic ketamine. Understanding first-pass metabolism is essential for interpreting these differences.
Enantiomers Beyond Ketamine
The principle of enantiomeric differences in drug action is not unique to ketamine. Many widely used medications exist as enantiomers with distinct properties:
- Amphetamine: Dextroamphetamine (the R-enantiomer) is more pharmacologically active than levoamphetamine and is the primary active component of several ADHD medications
- Omeprazole/Esomeprazole: The proton pump inhibitor omeprazole is racemic; esomeprazole is the purified S-enantiomer, marketed as having improved pharmacokinetics
- Ibuprofen: Only the S-enantiomer is pharmacologically active; the R-enantiomer is largely inert but is converted to the S-form in the body
These examples illustrate a broader pharmaceutical trend toward developing single-enantiomer drugs to achieve more predictable, potent, and potentially safer therapies.
Summary
Enantiomers are mirror-image molecular forms that can have profoundly different biological effects. In the context of ketamine, the distinction between S-ketamine (esketamine) and R-ketamine (arketamine) is central to understanding the drug's pharmacology, clinical applications, and future development. The ongoing investigation of each enantiomer's unique properties continues to shape ketamine research and may ultimately lead to more targeted, effective, and tolerable treatments for depression and other conditions.
References
- Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Psychiatry and Clinical Neurosciences, 2019 — Comprehensive review of ketamine enantiomers and metabolites
- Zanos P, Gould TD. Mechanisms of Ketamine Action as an Antidepressant. Molecular Psychiatry, 2018 — Detailed analysis of enantiomer-specific mechanisms
- Stereochemistry and Drug Action — National Center for Biotechnology Information (NCBI) — General reference on chirality in pharmacology
- Esketamine (Spravato) — FDA Drug Label — FDA prescribing information for the S-enantiomer formulation
- Yang C, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Translational Psychiatry, 2015 — Key preclinical study on arketamine's antidepressant properties
Share